These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11109161)

  • 21. Analysis of estrogen receptor alpha and beta in endometrial carcinomas: correlation with ER beta and clinicopathologic findings in 45 cases.
    Utsunomiya H; Suzuki T; Harada N; Ito K; Matsuzaki S; Konno R; Sato S; Yajima A; Sasano H
    Int J Gynecol Pathol; 2000 Oct; 19(4):335-41. PubMed ID: 11109162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations.
    Carcangiu ML; Chambers JT; Voynick IM; Pirro M; Schwartz PE
    Am J Clin Pathol; 1990 Sep; 94(3):247-54. PubMed ID: 1697729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients.
    Khabaz MN; Abdelrahman AS; Butt NS; Al-Maghrabi B; Al-Maghrabi J
    Ann Diagn Pathol; 2017 Oct; 30():47-51. PubMed ID: 28965628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
    Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status.
    Wang D; Konishi I; Koshiyama M; Mandai M; Nanbu Y; Ishikawa Y; Mori T; Fujii S
    Cancer; 1993 Nov; 72(9):2628-37. PubMed ID: 8104681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.
    Kato N; Watanabe J; Jobo T; Nishimura Y; Fujisawa T; Kamata Y; Kuramoto H
    J Cancer Res Clin Oncol; 2003 Apr; 129(4):222-6. PubMed ID: 12684894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
    Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.
    Kreizman-Shefer H; Pricop J; Goldman S; Elmalah I; Shalev E
    Diagn Pathol; 2014 Mar; 9():77. PubMed ID: 24684970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas.
    Cao QJ; Einstein MH; Anderson PS; Runowicz CD; Balan R; Jones JG
    Int J Gynecol Pathol; 2002 Apr; 21(2):147-54. PubMed ID: 11917224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of hPEBP4 negatively correlates with estrogen and progesterone receptors in endometrial carcinoma.
    Guo T; Li B; Gu C
    J BUON; 2013; 18(2):465-70. PubMed ID: 23818363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis.
    Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H
    Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Microsatellite instability in endometrial neoplasms correlation with clinicopathologic parameters and estrogen receptor or progesterone receptor status].
    Song Y; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 2000 May; 35(5):273-6. PubMed ID: 11775905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype.
    Mylona E; Tzelepis K; Theohari I; Giannopoulou I; Papadimitriou C; Nakopoulou L
    Histopathology; 2013 Feb; 62(3):472-80. PubMed ID: 23163571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of pS2 protein in endometrial carcinomas: correlation with clinicopathologic features and sex steroid receptor status.
    Koshiyama M; Yoshida M; Konishi M; Takemura M; Yura Y; Matsushita K; Hayashi M; Tauchi K
    Int J Cancer; 1997 Jun; 74(3):237-44. PubMed ID: 9221798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
    Soslow RA; Carlson DL; Horenstein MG; Osborne MP
    Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen and progesterone receptor expression in endometrial polyps.
    Mittal K; Schwartz L; Goswami S; Demopoulos R
    Int J Gynecol Pathol; 1996 Oct; 15(4):345-8. PubMed ID: 8886882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance.
    Sivridis E; Giatromanolaki A; Koukourakis MI; Georgiou L; Anastasiadis P
    Histopathology; 2002 Jan; 40(1):92-100. PubMed ID: 11903603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.